Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL) against the company’s biologics license application (BLA) seeking approval of ...

(NASDAQ:ATRA) can tell us which group is most powerful ... The gains from last week would have further boosted the one-year return to shareholders which currently stand at 16%. In the chart below, we ...